After a considerable wait (and considerable campaigning), in 2012, the South African Minister of Health, announced the award of a new antiretroviral tender -- worth R5.9 billion (£406,226,800).
For the first time since the ART program began, the tender includes a triple fixed-dose combination (FDC). The FDC is efavirenz/tenofovir/FTC for first line treatment and it is anticipated that over 90% of new patients will be eligible to initiate this FDC, including pregnant women.
The Southern African Clinicians Society advice document. Fixed-dose combination for adults accessing antiretroviral therapy. SAHIVMED Vol 14, No 1 (2013).
Links to other websites are current at date of posting but not maintained.